We demonstrated that ER+/PR− breast cancers are biologically characterized by relevant molecular characteristics in terms of prognostic and predictive information, which could be integrated into the clinical setting to realize the potentials of precision medicine in these clinically, and pathologically, challenging neoplasms. The gene discussed is ESR1; the disease is breast cancer.